Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The recognition of Outer Membrane Protein Complex (OMPC)-derived peptides presented on MHC class II molecules by CD4+ T-cell receptors (TCR) is a fundamental immunological interaction utilized in conjugate vaccine design. OMPC, sourced from Neisseria meningitidis serogroup B, acts as a potent carrier protein that facilitates a T-cell dependent immune response against covalently attached polysaccharide antigens (Donnelly et al., 1990, Journal of Immunology). Upon vaccination, B cells specific to the polysaccharide component internalize the conjugate, proteolytically process the OMPC protein, and display its peptides on the cell surface via MHC class II molecules. Specific CD4+ T cells recognize these peptide-MHC complexes through their TCRs, providing essential 'help' to B cells, which facilitates immunoglobulin class switching and the generation of long-term immunological memory. This mechanism is particularly vital for inducing protective immunity in infants against pathogens such as Haemophilus influenzae type b, as seen in vaccines like PedvaxHIB (FDA, 2021). Understanding this TCR-peptide-MHC II interaction is crucial for optimizing vaccine efficacy and ensuring robust protection across diverse patient populations.
The OMPC carrier protein is processed by antigen-presenting cells (APCs), such as B cells, into peptides that are loaded onto MHC class II molecules; these complexes are then recognized by specific CD4+ T-cell receptors, which triggers the release of cytokines and provides costimulatory signals necessary for B-cell differentiation and high-affinity antibody production (Pollard et al., 2009, Nature Reviews Immunology).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T-cell receptor recognition of Outer Membrane Protein Complex (OMPC)-derived peptide–MHC class II complexes (TCR-OMPC-MHC II).